Association between asthma and malignant tumors at the molecular level
DOI: 10.32364/2587-6821-2025-9-8-3
L.V. Radygina, M.N. Barybkina
All-Russian Institute of Scientific and Technical Information, Moscow, Russian Federation
This review presents current perspectives on asthma as a risk factor for the development of various oncological diseases, particularly lung cancer. The review discusses certain pharmacological agents that can be used for the simultaneous treatment of asthma and various types of malignant tumors (MTs), including lung cancer. In particular, inhaled corticosteroids and leukotriene receptor antagonists, which are employed in the management of asthma, may decrease the risk of oncological diseases. Additionally, the review describes the drugs tezepelumab and vandetanib, which possess both anti-asthmatic and anti-tumor activities. The review also explores the molecular association between asthma and MTs. A significant role in the development of both cancer and asthma is played by enzymes, such as matrix metalloproteinases, protein kinases, arginine methyltransferases, and arginase. Cytokines are also associated with the pathogenesis of asthma and malignancies — among them, transforming growth factor beta, thymic stromal lymphopoietin, and chemokines. Various receptors are involved in the progression of both MTs and asthma, including the adenosine receptor, Toll-like receptors, DNA receptors, receptors for glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, as well as costimulatory receptors. Other proteins, such as galectins, osteopontin, chitinase-3-like protein 1, and tissue factor, are linked to asthma and MTs. RNA also plays an important role in the development of these diseases. Special attention is given to programmed cell death — ferroptosis, pyroptosis, and cuproptosis — in the study of asthma and MTs.
Keywords: bronchial asthma, malignant neoplasms, lung cancer, enzymes, cytokines, receptors, proteins, RNA, programmed cell death.
For citation: Radygina L.V., Barybkina M.N. Association between asthma and malignant tumors at the molecular level. Russian Medical Inquiry. 2025;9(8):448–453 (in Russ.). DOI: 10.32364/2587-6821-2025-9-8-3
About the authors:
Lyubov V. Radygina — Researcher at the Department of Scientific Information "Life Sciences", All-Russian Institute of Scientific and Technical Information; 20, Usievich str., Moscow, 125315, Russian Federation; ORCID iD 0000-0003-2853-770X
Maria N. Barybkina — Researcher at the Department of Scientific Information "Life Sciences", All-Russian Institute of Scientific and Technical Information; 20, Usievich str., Moscow, 125315, Russian Federation; ORCID iD 0009-0007-9619-8992
Contact information: Lyubov V. Radygina, e-mail: lubarаdygina@yandex.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 18.04.2025.
Revised 19.05.2025.
Accepted 11.06.2025.
2. Ye L., Wang F., Wu H. et al. Evidence of the association between asthma and lung cancer risk fr om mendelian randomization analysis. Sci Rep. 2024;14(1):23047. DOI: 10.1038/s41598-024-74883-7
3. Huang Q., Huang Y., Xu S. et al. Association of asthma and lung cancer risk: A pool of cohort studies and Mendelian randomization analysis. Medicine (Baltimore). 2024;103(5):e35060. DOI: 10.1097/MD.0000000000035060
4. Lin Z., Yuan L., Zhang C. et al. Association of Bronchial Asthma with Lung Cancer: A Systematic Review and Meta-analysis. Iran J Allergy Asthma Immunol. 2024;23(4):347–356. DOI: 10.18502/ijaai.v23i4.16209
5. De Rubis G., Paudel K.R., Vishwas S. et al. Fecal microbiome extract downregulates the expression of key proteins at the interface between airway remodelling and lung cancer pathogenesis in vitro. Pathol Res Pract. 2024;260:155387. DOI: 10.1016/j.prp.2024.155387
6. Yanuck S.F. Failed Induction of the TH1 System in TH2 Dominant Patients: The Cancer-Permissive Immune Macroenvironment. Integr Med (Encinitas). 2024;23(2):24–35.
7. Woo A., Lee S.W., Koh H.Y. et al. Incidence of cancer after asthma development: 2 independent population-based cohort studies. J Allergy Clin Immunol. 2021;147(1):135–143. DOI: 10.1016/j.jaci.2020.04.041
8. Maeda-Minami A., Hosokawa M., Ishikura Y. et al. Relationship Between Leukotriene Receptor Antagonists on Cancer Development in Patients With Bronchial Asthma: A Retrospective Analysis. Anticancer Res. 2022;42(7):3717–3724. DOI: 10.21873/anticanres.15861
9. Shi L., Yu M., Jin Y. et al. A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases. Front Immunol. 2024;15:1442588. DOI: 10.3389/fimmu.2024.1442588
10. Zeng X., Xue L., Li W. et al. Vandetanib as a prospective anti-inflammatory and anti-contractile agent in asthma. Front Pharmacol. 2024;15:1345070. DOI: 10.3389/fphar.2024.1345070
11. Dorjay Tamang J.S., Banerjee S., Baidya S.K. et al. An overview of matrix metalloproteinase-12 in multiple disease conditions, potential selective inhibitors, and drug designing strategies. Eur J Med Chem. 2025;283:117154. DOI: 10.1016/j.ejmech.2024.117154
12. De Sanctis J.B., Garmendia J.V., Duchová H. et al. Lck Function and Modulation: Immune Cytotoxic Response and Tumor Treatment More Than a Simple Event. Cancers (Basel). 2024;16(15):2630. DOI: 10.3390/cancers16152630
13. Saleem S. Targeting MAPK signaling: A promising approach for treating inflammatory lung disease. Pathol Res Pract. 2024;254:155122. DOI: 10.1016/j.prp.2024.155122
14. Yang C., Rubin L., Yu X. et al. Preclinical evidence using synthetic compounds and natural products indicates that AMPK represents a potential pharmacological target for the therapy of pulmonary diseases. Med Res Rev. 2024;44(3):1326–1369. DOI: 10.1002/med.22014
15. Kot A., Koszewska D., Ochman B. et al. Clinical Potential of Misshapen/NIKs-Related Kinase (MINK) 1-A Many-Sided Element of Cell Physiology and Pathology. Curr Issues Mol Biol. 2024;46(12):13811–13845. DOI: 10.3390/cimb46120826
16. Zhou S., Zhang Q., Yang H. et al. Targeting type I PRMTs as promising targets for the treatment of pulmonary disorders: Asthma, COPD, lung cancer, PF, and PH. Life Sci. 2024;342:122538. DOI: 10.1016/j.lfs.2024.122538
17. Gzik A., Borek B., Chrzanowski J. et al. Novel orally bioavailable piperidine derivatives as extracellular arginase inhibitors developed by a ring expansion. Eur J Med Chem. 2024;264:116033. DOI: 10.1016/j.ejmech.2023.116033
18. Plichta J., Panek M. Role of the TGF-β cytokine and its gene polymorphisms in asthma etiopathogenesis. Front Allergy. 2025;6:1529071. DOI: 10.3389/falgy.2025.1529071
19. Kundra S., Kaur R., Pasricha C. et al. Pathological insights into activin A: Molecular underpinnings and therapeutic prospects in various diseases. Int Immunopharmacol. 2024;139:112709. DOI: 10.1016/j.intimp.2024.112709
20. Liu X., Han J., Wang Q. et al. Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential. Antib Ther. 2024;7(2):123–130. DOI: 10.1093/abt/tbae006
21. Bao Y., Tong C., Xiong X. CXCL3: A key player in tumor microenvironment and inflammatory diseases. Life Sci. 2024;348:122691. DOI: 10.1016/j.lfs.2024.122691
22. Li Y., Geng W.L., Li C.C. et al. Progress of CCL20-CCR6 in the airways: a promising new therapeutic target. J Inflamm (Lond). 2024;21(1):54. DOI: 10.1186/s12950-024-00427-5
23. Gulati N., Chellappan D.K., MacLoughlin R. et al. Advances in nano-based drug delivery systems for the management of cytokine influx-mediated inflammation in lung diseases. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(6):3695–3707. DOI: 10.1007/s00210-023-02882-y
24. Gao Z.G., Haddad M., Jacobson K.A. A2B adenosine receptor signaling and regulation. Purinergic Signal. 2025;21(2):201–220. DOI: 10.1007/s11302-024-10025-y
25. Strašek Benedik N., Dolšak A., Švajger U. et al. Structural Optimization and Biological Evaluation of Isoxazolo[5.4 -d]pyrimidines as Selective Toll-Like Receptor 7 Agonists. ACS Omega. 2024;9(2):2362–2382. DOI: 10.1021/acsomega.3c06343
26. Qian J.H., Ye L., Tan Y. [Research progress on the cyclic GMP-AMP synthase stimulator of interferon genes pathway in respiratory diseases]. Zhonghua Jie He He Hu Xi Za Zhi. 2024;47(3):252–258 (in Chinese). DOI: 10.3760/cma.j.cn112147-20231020-00251
27. Janić M., Škrgat S., Harlander M. et al. Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Wh ere Are We at? Medicina (Kaunas). 2024;60(12):2030. DOI: 10.3390/medicina60122030
28. Xu C., Meng X., Chai P. et al. Directed Evolution of Multicyclic Peptides Using Yeast Display for Sensitive and Selective Fluorescent Analysis of CD28 on the Cell Surface. Anal Chem. 2025;97(7):4031–4040. DOI: 10.1021/acs.analchem.4c05681
29. Portacci A., Iorillo I., Maselli L. et al. The Role of Galectins in Asthma Pathophysiology: A Comprehensive Review. Curr Issues Mol Biol. 2024;46(5):4271–4285. DOI: 10.3390/cimb46050260
30. Jia Q., Yang Y., Yao S. et al. Emerging Roles of Galectin-3 in Pulmonary Diseases. Lung. 2024;202(4):385–403. DOI: 10.1007/s00408-024-00709-y
31. Jia Q., Ouyang Y., Yang Y. et al. Osteopontin: A Novel Therapeutic Target for Respiratory Diseases. Lung. 2024;202(1):25–39. DOI: 10.1007/s00408-023-00665-z
32. Chang M.C., Chen C.T., Chiang P.F. et al. The Role of Chitinase-3-like Protein-1 (YKL40) in the Therapy of Cancer and Other Chronic-Inflammation-Related Diseases. Pharmaceuticals (Basel). 2024;17(3):307. DOI: 10.3390/ph17030307
33. Fan Y., Meng Y., Hu X. et al. Uncovering novel mechanisms of chitinase-3-like protein 1 in driving inflammation-associated cancers. Cancer Cell Int. 2024;24(1):268. DOI: 10.1186/s12935-024-03425-y
34. Heidari Z., Naeimzadeh Y., Fallahi J. et al. The Role of Tissue Factor In Signaling Pathways of Pathological Conditions and Angiogenesis. Curr Mol Med. 2024;24(9):1135–1151. DOI: 10.2174/0115665240258746230919165935
35. Liu X., Chen Q., Jiang S. et al. MicroRNA-26a in respiratory diseases: mechanisms and therapeutic potential. Mol Biol Rep. 2024;51(1):627. DOI: 10.1007/s11033-024-09576-5
36. Lv J., Xiong X. Extracellular Vesicle microRNA: A Promising Biomarker and Therapeutic Target for Respiratory Diseases. Int J Mol Sci. 2024;25(17):9147. DOI: 10.3390/ijms25179147
37. Li H., Yang J., Qin Y. et al. Research progress on the role of N6-methyladenosine methylation in the pathogenesis and development of respiratory diseases. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024;36(3):303–307. DOI: 10.3760/cma.j.cn121430-20230223-00108
38. Vu Thi H., Tran L.T., Nguyen H.Q. et al. RNA therapeutics for respiratory diseases. Prog Mol Biol Transl Sci. 2024;203:257–271. DOI: 10.1016/bs.pmbts.2023.12.021
39. Neary M.T., Mulder L.M., Kowalski P.S. et al. Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol. J Control Release. 2024;366:812–833. DOI: 10.1016/j.jconrel.2023.12.012
40. Xu M., Zhang D., Yan J. Targeting ferroptosis using Chinese herbal compounds to treat respiratory diseases. Phytomedicine. 2024;130:155738. DOI: 10.1016/j.phymed.2024.155738
41. Panganiban R.A., Nadeau K.C., Lu Q. Pyroptosis, gasdermins and allergic diseases. Allergy. 2024;79(9):2380–2395. DOI: 10.1111/all.16236
42. Song W., Yue Y., Zhang Q. et al. Copper homeostasis dysregulation in respiratory diseases: a review of current knowledge. Front Physiol. 2024;15:1243629. DOI: 10.3389/fphys.2024.1243629
This work is licensed under a Creative Commons «Attribution» 4.0 License.
